Views: 79

Harvard Infectious Diseases in Adults 2021

Product code : 1626270740


    Harvard Infectious Diseases in Adults 2021

    State-of-the-Art Approaches to Prevention, Diagnosis, and Treatment of Infectious Diseases

    Highlights of the 2021 Program
    Expanded Case-Based and Problem-Solving Education
    The 2021 program features an expanded range of interactive, case-based and problem-solving education. The formats are engaging and attendees are encouraged to pose questions of our national experts in Q and A sessions following the lectures and the workshops.
    Treating Highly Resistant Infections, including:

    MRSA and VISA (vancomycin-intermediate Staph aureus)
    Extended spectrum beta-lactamase (ESBL)-producing gram negative rods
    Carbapenemase-producing gram negative rods, including the NDM-1 metallo-beta-lactamase-producing organisms
    Vancomycin-resistant enterococci (VRE)
    Aspergillus and  non-aspergillus mold infections
    Candida auris
    Nontuberculous mycobacteria (NTM)

    Common Infectious Diseases: Updates in Prevention, Diagnosis, and Treatment
    Updates to keep you current on new strategies, state-of-the-art practices, and the most recent guidelines to address:

    Infections in the expanding populations of immunocompromised hosts
    Infections in persons with substance use disorders
    Infections of travelers and foreign-born persons
    Systemic fungal infections
    Native and device-related orthopedic infections
    Central nervous system (CNS) infections
    Ear, nose and throat (ENT) and eye infections
    Bronchiectasis and pneumonia
    HIV and its infectious and noninfectious complications
    PEP (Post-Exposure Prophylaxis) and PrEP (Pre-Exposure Prophylaxis) to prevent HIV infection
    Sexually transmitted infections
    Hepatitis B and C infections
    Tick- and mosquito-borne infections
    Vaccines and vaccine-preventable infections
    Clostridioides difficile infection

    Challenging, Rare, and Emerging Infectious Diseases
    Comprehensive updates on:

    EEE, Zika, Ebola, Middle Eastern Respiratory Syndrome (MERS), and other emerging infectious diseases
    Re-emergence of vaccine-preventable diseases
    Pulmonary and extrapulmonary non-tuberculous (“atypical”) mycobacteria, including Mycobacterium abscessus
    Global infectious diseases of clinical importance

    Clinical Decision-Making
    Hear directly from world-renowned specialists and master clinicians on their approach and decision-making criteria for:

    Selecting the best antimicrobial and duration of treatment
    Rapid detection and empiric treatment of the life-threatening infectious diseases
    Inpatient or outpatient treatment, and the outpatient antibiotic transition: IV or oral?
    Optimizing empiric antimicrobial therapy: what to start, when to narrow or stop

    Our multidisciplinary talks and workshops incorporate safety, quality, and practice improvement in infectious diseases, including:

    Antimicrobial stewardship to prevent resistance and reduce cost
    Infection control, including biothreats
    Early inpatient ID consultations to improve outcomes
    Strategies for management of infection in persons who inject drugs (PWID)

    Optimized for Remote Education
    The 2021 program has been enhanced for distance learning. In addition to being live streamed, all sessions will be recorded and made available to participants for online viewing for 30 days after the end of the course.